Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IO Biomarkers: Where Do We Stand In 2017?

Executive Summary

Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.

Advertisement

Related Content

Keytruda Approval Opens New Routes For Immuno-Oncology
How Immuno-Oncology Is Turning Biomarker Development On Its Head
Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda
Building A Better Biomarker: PD-L1 Expression Under Spotlight At ASCO
Roche Sees Biomarker Data As Support For Immuno-Oncology Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel